Business Trends– category –
-
Nanotechnology-Based Drug Delivery Systems Drive Personalized Medicine with Approved Formulations for Diverse Diseases
IJSRT Journal India Overview Nanotechnology-based Drug Delivery Systems (NDDS) have overcome limitations of conventional therapies by enhancing drug solubility, absorption, stability, and bioavailability, enabling targeted delivery to sp... -
Cytiva Advances In Vivo CAR-T Therapy with Targeted mRNA-LNP Delivery to the Spleen
Cytiva スウェーデン Overview Cytiva is making significant strides in *in vivo* CAR-T therapy by utilizing advanced lipid nanoparticle (LNP) systems for direct T cell reprogramming within patients. This innovative approach extends LNP del... -
Argo Graphene Solutions Closes License Agreement for Grapherry’s STREAM Graphene Production Platform
Newsfile Corp. via StockTitan Canada Overview Argo Graphene Solutions Corp. has finalized a license agreement with Grapherry, Inc. for Grapherry's proprietary STREAM graphene production platform and related intellectual property. Grapher... -
Beam Therapeutics Receives FDA IND Clearance for Liver-Targeted LNP Formulation BEAM-304 for Phenylketonuria (PKU) Treatment
Beam Therapeutics USA Overview Beam Therapeutics announced FDA IND clearance for BEAM-304, a liver-targeting lipid-nanoparticle (LNP) formulation of base editing reagents, for the treatment of Phenylketonuria (PKU). Designed to correct m... -
Samsung Biologics Expands Bio R&D Center Beyond CDMO Support, Investing in Next-Gen Modalities, AI, and Machine Learning
Korea Biomedical Review (KBR) South Korea Overview Samsung Biologics is significantly expanding its Bio R&D Center beyond traditional Contract Development and Manufacturing Organization (CDMO) support. The company is focusing on thre... -
Synthetic Biology Firm Syntax Bio Expands Series A to $14.4M, Boosting Preclinical Research for CRISPR-Based Type 1 Diabetes Beta-Cell Therapy
Fierce Biotech USA Overview Synthetic biology company Syntax Bio announced an expansion of its Series A funding round to $14.4 million, pushing total capital raised over $25 million. This capital injection will primarily drive the develo... -
Takeda Exits Cell Therapy, Shifts Strategy to AI Drug Discovery with Additional 4,500 Job Cuts in Restructuring
BioSpace USA Overview Takeda Pharmaceutical Company is undergoing a major restructuring, including a complete exit from cell therapy, to navigate 'existential risks,' shifting its focus to 'frontier science' such as AI-driven drug discov... -
Prime Medicine Secures NZ Clinical Trial Clearance for Prime Editing Therapy PM577a in H1069Q-Mutated Wilson Disease, Initiating Global Phase 1/2 Study
GlobeNewswire (Prime Medicine Press Release) USA Overview Prime Medicine has announced the approval of its Clinical Trial Application (CTA) in New Zealand for PM577a, an investigational prime editing therapy for H1069Q-mutated Wilson dis... -
CAR-T Expands to Solid Tumors & Autoimmune Diseases; BAF CAR-T Shows Promising Early Results for Lupus, Compared with Off-the-Shelf CAR-NK Cells
University Hospitals USA Overview CAR-T cell therapy is expanding its success from hematologic malignancies to solid tumors and autoimmune diseases. Notably, early clinical trial results for BAF CAR-T in lupus are highly promising, sugge... -
Fate Therapeutics’ iPSC-Derived CAR-T FT836 Shows Early Phase 1 Data Suggesting Colorectal Tumor Shrinkage with Nine Engineered Edits
CRISPR Medicine News USA Overview Fate Therapeutics has announced initial Phase 1 data for FT836, an iPSC-derived, off-the-shelf CAR-T cell therapy. In a trial involving nine colorectal cancer patients, reductions in target lesion size a...
